Cargando…
Basal Tumor Cell Isolation and Patient-Derived Xenograft Engraftment Identify High-Risk Clinical Bladder Cancers
Strategies to identify tumors at highest risk for treatment failure are currently under investigation for patients with bladder cancer. We demonstrate that flow cytometric detection of poorly differentiated basal tumor cells (BTCs), as defined by the co-expression of CD90, CD44 and CD49f, directly f...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5075783/ https://www.ncbi.nlm.nih.gov/pubmed/27775025 http://dx.doi.org/10.1038/srep35854 |
_version_ | 1782461930894524416 |
---|---|
author | Skowron, K. B. Pitroda, S. P. Namm, J. P. Balogun, O. Beckett, M. A. Zenner, M. L. Fayanju, O. Huang, X. Fernandez, C. Zheng, W. Qiao, G. Chin, R. Kron, S. J. Khodarev, N. N. Posner, M. C. Steinberg, G. D. Weichselbaum, R. R. |
author_facet | Skowron, K. B. Pitroda, S. P. Namm, J. P. Balogun, O. Beckett, M. A. Zenner, M. L. Fayanju, O. Huang, X. Fernandez, C. Zheng, W. Qiao, G. Chin, R. Kron, S. J. Khodarev, N. N. Posner, M. C. Steinberg, G. D. Weichselbaum, R. R. |
author_sort | Skowron, K. B. |
collection | PubMed |
description | Strategies to identify tumors at highest risk for treatment failure are currently under investigation for patients with bladder cancer. We demonstrate that flow cytometric detection of poorly differentiated basal tumor cells (BTCs), as defined by the co-expression of CD90, CD44 and CD49f, directly from patients with early stage tumors (T1-T2 and N0) and patient-derived xenograft (PDX) engraftment in locally advanced tumors (T3-T4 or N+) predict poor prognosis in patients with bladder cancer. Comparative transcriptomic analysis of bladder tumor cells isolated from PDXs indicates unique patterns of gene expression during bladder tumor cell differentiation. We found cell division cycle 25C (CDC25C) overexpression in poorly differentiated BTCs and determined that CDC25C expression predicts adverse survival independent of standard clinical and pathologic features in bladder cancer patients. Taken together, our findings support the utility of BTCs and bladder cancer PDX models in the discovery of novel molecular targets and predictive biomarkers for personalizing oncology care for patients. |
format | Online Article Text |
id | pubmed-5075783 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-50757832016-10-28 Basal Tumor Cell Isolation and Patient-Derived Xenograft Engraftment Identify High-Risk Clinical Bladder Cancers Skowron, K. B. Pitroda, S. P. Namm, J. P. Balogun, O. Beckett, M. A. Zenner, M. L. Fayanju, O. Huang, X. Fernandez, C. Zheng, W. Qiao, G. Chin, R. Kron, S. J. Khodarev, N. N. Posner, M. C. Steinberg, G. D. Weichselbaum, R. R. Sci Rep Article Strategies to identify tumors at highest risk for treatment failure are currently under investigation for patients with bladder cancer. We demonstrate that flow cytometric detection of poorly differentiated basal tumor cells (BTCs), as defined by the co-expression of CD90, CD44 and CD49f, directly from patients with early stage tumors (T1-T2 and N0) and patient-derived xenograft (PDX) engraftment in locally advanced tumors (T3-T4 or N+) predict poor prognosis in patients with bladder cancer. Comparative transcriptomic analysis of bladder tumor cells isolated from PDXs indicates unique patterns of gene expression during bladder tumor cell differentiation. We found cell division cycle 25C (CDC25C) overexpression in poorly differentiated BTCs and determined that CDC25C expression predicts adverse survival independent of standard clinical and pathologic features in bladder cancer patients. Taken together, our findings support the utility of BTCs and bladder cancer PDX models in the discovery of novel molecular targets and predictive biomarkers for personalizing oncology care for patients. Nature Publishing Group 2016-10-24 /pmc/articles/PMC5075783/ /pubmed/27775025 http://dx.doi.org/10.1038/srep35854 Text en Copyright © 2016, The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Article Skowron, K. B. Pitroda, S. P. Namm, J. P. Balogun, O. Beckett, M. A. Zenner, M. L. Fayanju, O. Huang, X. Fernandez, C. Zheng, W. Qiao, G. Chin, R. Kron, S. J. Khodarev, N. N. Posner, M. C. Steinberg, G. D. Weichselbaum, R. R. Basal Tumor Cell Isolation and Patient-Derived Xenograft Engraftment Identify High-Risk Clinical Bladder Cancers |
title | Basal Tumor Cell Isolation and Patient-Derived Xenograft Engraftment Identify High-Risk Clinical Bladder Cancers |
title_full | Basal Tumor Cell Isolation and Patient-Derived Xenograft Engraftment Identify High-Risk Clinical Bladder Cancers |
title_fullStr | Basal Tumor Cell Isolation and Patient-Derived Xenograft Engraftment Identify High-Risk Clinical Bladder Cancers |
title_full_unstemmed | Basal Tumor Cell Isolation and Patient-Derived Xenograft Engraftment Identify High-Risk Clinical Bladder Cancers |
title_short | Basal Tumor Cell Isolation and Patient-Derived Xenograft Engraftment Identify High-Risk Clinical Bladder Cancers |
title_sort | basal tumor cell isolation and patient-derived xenograft engraftment identify high-risk clinical bladder cancers |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5075783/ https://www.ncbi.nlm.nih.gov/pubmed/27775025 http://dx.doi.org/10.1038/srep35854 |
work_keys_str_mv | AT skowronkb basaltumorcellisolationandpatientderivedxenograftengraftmentidentifyhighriskclinicalbladdercancers AT pitrodasp basaltumorcellisolationandpatientderivedxenograftengraftmentidentifyhighriskclinicalbladdercancers AT nammjp basaltumorcellisolationandpatientderivedxenograftengraftmentidentifyhighriskclinicalbladdercancers AT baloguno basaltumorcellisolationandpatientderivedxenograftengraftmentidentifyhighriskclinicalbladdercancers AT beckettma basaltumorcellisolationandpatientderivedxenograftengraftmentidentifyhighriskclinicalbladdercancers AT zennerml basaltumorcellisolationandpatientderivedxenograftengraftmentidentifyhighriskclinicalbladdercancers AT fayanjuo basaltumorcellisolationandpatientderivedxenograftengraftmentidentifyhighriskclinicalbladdercancers AT huangx basaltumorcellisolationandpatientderivedxenograftengraftmentidentifyhighriskclinicalbladdercancers AT fernandezc basaltumorcellisolationandpatientderivedxenograftengraftmentidentifyhighriskclinicalbladdercancers AT zhengw basaltumorcellisolationandpatientderivedxenograftengraftmentidentifyhighriskclinicalbladdercancers AT qiaog basaltumorcellisolationandpatientderivedxenograftengraftmentidentifyhighriskclinicalbladdercancers AT chinr basaltumorcellisolationandpatientderivedxenograftengraftmentidentifyhighriskclinicalbladdercancers AT kronsj basaltumorcellisolationandpatientderivedxenograftengraftmentidentifyhighriskclinicalbladdercancers AT khodarevnn basaltumorcellisolationandpatientderivedxenograftengraftmentidentifyhighriskclinicalbladdercancers AT posnermc basaltumorcellisolationandpatientderivedxenograftengraftmentidentifyhighriskclinicalbladdercancers AT steinberggd basaltumorcellisolationandpatientderivedxenograftengraftmentidentifyhighriskclinicalbladdercancers AT weichselbaumrr basaltumorcellisolationandpatientderivedxenograftengraftmentidentifyhighriskclinicalbladdercancers |